All In Biotech

Drug Trial Radar · NCT07605962

Phase 1/2 Study of UI-102 in Selected Advanced Cancers

A Phase I/II Open-Label, Dose Escalation, Dose Optimization, and Cohort Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of UI-102, a Novel Cholesteryl Pullulan (CHP) Nanoparticle-formulated TLR7/8 Agonist in Patients With Selected Locally Advanced and/or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

May 20, 2026

Primary completion

Mar 31, 2030

Study completion Mar 31, 2031

Sponsor

Lead sponsor
United Immunity, co., Ltd.Industry
Sponsor type
Industry
First posted
May 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase 1/2 first-in-human study is designed to assess the safety and efficacy of UI-102, a TLR7/8 agonist encapsulated in a Cholesteryl Pullulan Nanoparticle.

Conditions

  • Advanced Cancer

Interventions

  • UI-102Drug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation: Percentage of participants with ≥1 dose-limiting toxicity (DLT)Time frame: Up to 24 months
  2. Dose Escalation: Percentage of participants with ≥1 adverse event (AE)Time frame: Up to 24 months
  3. Dose Escalation: Percentage of participants with ≥1 serious adverse event (SAE)Time frame: Up to 24 months
  4. Dose Escalation: Percentage of participants with significant changes in electrocardiogram (ECG) recordingsTime frame: Up to 24 months
  5. Dose Escalation: Percentage of participants with significant changes in vital signsTime frame: Up to 24 months
  6. Dose Escalation: Percentage of participants with significant changes in laboratory resultsTime frame: Up to 24 months
  7. Dose Escalation: Percentage of participants with a dose interruption, reduction, or discontinuationTime frame: Up to 24 months
  8. Expansion: Best Overall Response (BOR) as Determined by RECIST v1.1Time frame: Up to 48 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • NEXT Oncology

    Dallas, Texas · Recruiting

  • NEXT Oncology

    Houston, Texas · Recruiting

  • NEXT Oncology

    San Antonio, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.